What this is
- How it works
- How it works isn't classified yet
- Tested for
- Adenoid Cystic Carcinoma, Colorectal Cancer
- Main trialPhase 1
- “Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC”In the company’s words, NCT06462183 on ClinicalTrials.gov
Other drugs for Adenoid Cystic Carcinoma
- GotistobartOncoC4 · BioNTech · Phase 1/2
- Emi-LeDay One Biopharmaceuticals, Inc. · Phase 1/2
- IvonescimabAkeso · Summit Therapeutics · Phase 2
- REM-422Remix Therapeutics · Phase 1/2
- VMD-928VM Oncology, LLC · Phase 1/2
- HG146HitGen Inc. · Phase 2
Coming up1
- Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Dec 2027 | Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026